192 related articles for article (PubMed ID: 20140822)
1. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia.
Mongelard F; Bouvet P
Curr Opin Mol Ther; 2010 Feb; 12(1):107-14. PubMed ID: 20140822
[TBL] [Abstract][Full Text] [Related]
2. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
[TBL] [Abstract][Full Text] [Related]
3. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
[TBL] [Abstract][Full Text] [Related]
4. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
5. Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.
Ferrara B; Belbekhouche S; Habert D; Houppe C; Vallée B; Bourgoin-Voillard S; Cohen JL; Cascone I; Courty J
Nanotechnology; 2021 May; 32(32):. PubMed ID: 33892482
[TBL] [Abstract][Full Text] [Related]
6. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
7. Leukemia: A model for drug development.
Keating MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2598-604. PubMed ID: 9815664
[TBL] [Abstract][Full Text] [Related]
8. Targeting nucleolin to obstruct vasculature feeding with an intelligent DNA nanorobot.
Li H; Liu J; Gu H
J Cell Mol Med; 2019 Mar; 23(3):2248-2250. PubMed ID: 30592140
[TBL] [Abstract][Full Text] [Related]
9. Nucleolin antisense oligodeoxynucleotides induce apoptosis and may be used as a potential drug for nasopharyngeal carcinoma therapy.
Wu CD; Chou HW; Kuo YS; Lu RM; Hwang YC; Wu HC; Lin CT
Oncol Rep; 2012 Jan; 27(1):94-100. PubMed ID: 21956494
[TBL] [Abstract][Full Text] [Related]
10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
11. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
12. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
13. The development and testing of aptamers for cancer.
Barbas AS; White RR
Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
[TBL] [Abstract][Full Text] [Related]
14. Aptamer-based tumor-targeted drug delivery for photodynamic therapy.
Shieh YA; Yang SJ; Wei MF; Shieh MJ
ACS Nano; 2010 Mar; 4(3):1433-42. PubMed ID: 20166743
[TBL] [Abstract][Full Text] [Related]
15. Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells.
Lee KY; Kang H; Ryu SH; Lee DS; Lee JH; Kim S
J Biomed Biotechnol; 2010; 2010():168306. PubMed ID: 20204158
[TBL] [Abstract][Full Text] [Related]
16. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
Vassilakos A; Lee Y; Viau S; Feng N; Jin H; Chai V; Wang M; Avolio T; Wright J; Young A
Int J Oncol; 2009 Jan; 34(1):33-42. PubMed ID: 19082475
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Rosenberg JE; Bambury RM; Van Allen EM; Drabkin HA; Lara PN; Harzstark AL; Wagle N; Figlin RA; Smith GW; Garraway LA; Choueiri T; Erlandsson F; Laber DA
Invest New Drugs; 2014 Feb; 32(1):178-87. PubMed ID: 24242861
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
19. Nucleolar localization of aprataxin is dependent on interaction with nucleolin and on active ribosomal DNA transcription.
Becherel OJ; Gueven N; Birrell GW; Schreiber V; Suraweera A; Jakob B; Taucher-Scholz G; Lavin MF
Hum Mol Genet; 2006 Jul; 15(14):2239-49. PubMed ID: 16777843
[TBL] [Abstract][Full Text] [Related]
20. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature.
Fogal V; Sugahara KN; Ruoslahti E; Christian S
Angiogenesis; 2009; 12(1):91-100. PubMed ID: 19225898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
